Structural basis for repurposing a 100-years-old drug suramin for treating COVID-19
Yin, W.; Luan, X.; Li, Z.; Zhang, L.; Zhou, Z.; Gao, M.; Wang, X.; Zhou, F.; Shi, J.; You, E.; Liu, M.; Wang, Q.; Wang, Q.; Jiang, Y.; Jiang, H.; Xiao, G.; Yu, X.; Zhang, S.; Xu, H. E.
Show abstract
The COVID-19 pandemic by non-stop infections of SARS-CoV-2 has continued to ravage many countries worldwide. Here we report the discovery of suramin, a 100-year-old drug, as a potent inhibitor of the SARS-CoV-2 RNA dependent RNA polymerase (RdRp) through blocking the binding of RNA to the enzyme. In biochemical assays, suramin and its derivatives are at least 20-fold more potent than remdesivir, the currently approved nucleotide drug for COVID-19. The 2.6 [A] cryo-EM structure of the viral RdRp bound to suramin reveals two binding sites of suramin, with one site directly blocking the binding of the RNA template strand and the other site clash with the RNA primer strand near the RdRp catalytic active site, therefore inhibiting the viral RNA replication. Furthermore, suramin potently inhibits SARS-CoV-2 duplication in Vero E6 cells. These results provide a structural mechanism for the first non-nucleotide inhibitor of the SARS-CoV-2 RdRp and a rationale for repurposing suramin for treating COVID-19. One Sentence SummaryDiscovery and mechanism of suramin as potent SARS-CoV-2 RNA polymerase inhibitor and its repurposing for treating COVID-19.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04 95%
- Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages 94%
- Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD 94%
Similar papers in this journal
- Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2 94%
- Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies 93%
- MAAD: Multidimensional Antiviral Antibody Database 91%
Similar papers in this journal
Similar papers in this journal
- Structural Insights into the Assembly and Regulation of 2'-O RNA Methylation by SARS-CoV-2 nsp16/nsp10 95%
- Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing 95%
- A common binding motif in the ET domain of BRD3 forms polymorphic structural interfaces with host and viral proteins 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.